Stockscreener 앱 받기
13.30
3.69%
-0.51
Bioventus Inc 주식(BVS)의 최신 뉴스
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Bioventus Inc. (NASDAQ: BVS) - Lelezard
Bank of New York Mellon Corp Takes Position in Bioventus Inc. $BVS - MarketBeat
Bioventus Stock Price Forecast. Should You Buy BVS? - StockInvest.us
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Bioventus (NASDAQ:BVS) Gains As Healthcare Demand Supports Growth - Kalkine Media
Bioventus Inc. (NASDAQ:BVS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Bioventus Inc (BVS) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
BIOVENTUS INC. (BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of The Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (BVS) - TMX Newsfile
Bioventus Inc. (BVS) Holds Steady Near $13.84 as Investors Weigh Support and ResistanceExhaustion Gap - siam.in
Bioventus Inc. (BVS) Holds Steady Near $13.84 as Investors Weigh Support and ResistanceImbalance Zone - dars.gov.et
Bioventus Inc. Class A (BVS) Peer Comparison – Compare with Others - Value Research
Bioventus Inc. Class A (BVS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Are Investors Undervaluing Bioventus (BVS) Right Now? - qz.com
Globeflex Capital L P Purchases New Shares in Bioventus Inc. $BVS - marketbeat.com
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS) - easternprogress.com
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth - Eastern Progress
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? - Eastern Progress
Can Bioventus (NASDAQ:BVS) Keep Its Momentum Going? - Kalkine Media
BVS Maintains Buy Rating by Canaccord Genuity -- Price Target Ra - GuruFocus
BVS Reiterated by Cantor Fitzgerald -- Price Target Maintained a - GuruFocus
Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
CCORF Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $19 - Moomoo
Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
(BVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bioventus (BVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Bioventus (BVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Bioventus (BVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Dimensional Fund Advisors LP Increases Position in Bioventus Inc. $BVS - MarketBeat
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance - Yahoo Finance
Bioventus (NASDAQ:BVS) Gains Attention After Strong Quarterly Update - Kalkine Media
Sei Investments Co. Boosts Holdings in Bioventus Inc. $BVS - MarketBeat
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump - Sahm
Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump - webull.com
Bioventus Inc. (BVS) Stock Analysis: Healthcare Innovator With 5.87% Upside Potential - DirectorsTalk Interviews
Bioventus Inc (BVS) Stock News Today - TradingKey
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bioventus Inc (BVS) Stock News Today - TradingKey
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump - simplywall.st
Bioventus Inc. $BVS Shares Sold by Renaissance Technologies LLC - MarketBeat
Latham & Watkins Advises Bioventus in Review of Strategic Alternatives - Latham & Watkins LLP
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Bioventus Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain - simplywall.st
Bioventus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
7.19%
자본화:
|
볼륨(24시간):